Newamsterdam Pharma Company N.V. (NAMS) Stock Price, Quote & News

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewA...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 35 206 2971

Website: www.newamsterdampharma.com

Address:

Gooimeer 2-35, Naarden, Netherlands

masonat Jul. 21 at 3:06 PM

$NAMS overview of the REMBRANDT trial that will read out shortly after PREVAIL. I would venture to guess that obicetrapib will have more data supporting its use at launch than any LLT has ever had at launch. https://www.sciencedirect.com/science/article/pii/S0002870325002212

1 · Reply

JarvisFlow Jul. 17 at 11:30 AM

Goldman Sachs has updated their rating for NewAmsterdam Pharma Co ( $NAMS ) to Neutral with a price target of 27.

0 · Reply

Jakeipedia Jul. 12 at 1:03 PM

$VRNA what a massive windfall!!! I’m holding till close Next load for me $MLYS watching $NAMS because of the leadership. Any biotech ideas please share.

3 · Reply

RunnerSignals Jul. 10 at 8:50 PM

comeback kings flex $ACDC $PHAT $PRME $TALO $NAMS bounce off lows, closing the day with a victory dance!

0 · Reply

masonat Jul. 10 at 2:56 PM

$NAMS $XBI the Alzheimer's Association, which presumably has already seen the biomarker data being presented at their conference this month, is very bullish on obicetrapib. https://www.alz.org/news/2025/topline-results-broadway-clinical-trial-obicetrapib-alzheimers

0 · Reply

newfguy Jul. 9 at 7:15 PM

$NAMS looks like insiders recognize value and potential

0 · Reply

JFDI Jul. 9 at 2:29 PM

$NAMS perking up

0 · Reply

Biobullshitsniffer Jul. 4 at 8:37 AM

$NAMS That Alzeihmer data in July 27 to 31 is expected to be crap right?

1 · Reply

8869scy Jul. 1 at 6:22 PM

$NAMS Don't think I can hang onto my position much longer. A year ago today stock was trading at 19, now trading at 18. I am bullish on their statin alternative to control ldl, I see a real market for it but man this stock is a DOG.

2 · Reply

TrendEdgeLogan Jun. 28 at 5:27 PM

$NAMS $2.44B mc, founder-led. $XBI stock to watch due to ongoing unplanned open market share purchases, including last week. Director bought $69K in shares, adding to his $167K bullish bet from the prior week. - Pct of funds long is increasing long-term but fell last quarter - Short float pct is rising long-term, a conflicting signal to monitor ⚠️ TrendEdge.app/asset/NAMS

0 · Reply

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jun 9, 2025, 7:00 AM EDT - 6 weeks ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 5, 2025, 8:00 AM EDT - 6 weeks ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

May 27, 2025, 8:00 AM EDT - 2 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 14, 2025, 8:00 AM EDT - 2 months ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 2 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 7, 2025, 7:15 AM EDT - 2 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 2, 2025, 4:01 PM EDT - 2 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2025, 8:00 AM EDT - 3 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Mar 31, 2025, 8:00 AM EDT - 4 months ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 28, 2025, 11:26 PM EST - 5 months ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 10:48 AM EST - 5 months ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 26, 2025, 8:00 AM EST - 5 months ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 8:00 AM EST - 5 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Dec 13, 2024, 5:16 PM EST - 7 months ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 11, 2024, 9:37 PM EST - 7 months ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 1:33 PM EST - 7 months ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 11, 2024, 6:55 AM EST - 8 months ago

Top 3 Health Care Stocks That May Collapse This Quarter

ADPT FNA

Dec 10, 2024, 4:34 PM EST - 8 months ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 11:14 AM EST - 8 months ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 7:00 AM EST - 8 months ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Nov 18, 2024, 3:20 PM EST - 8 months ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Oct 28, 2024, 4:30 PM EDT - 9 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 4, 2024, 12:09 PM EDT - 10 months ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Aug 30, 2024, 8:00 AM EDT - 11 months ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 1:33 PM EDT - 11 months ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 8, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 5, 2024, 1:40 PM EDT - 1 year ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

Apr 9, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 1 year ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 1, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Mar 25, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 12, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Feb 28, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 13, 2024, 10:40 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 1, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

Nov 13, 2023, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

Oct 23, 2023, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

Oct 17, 2023, 3:00 AM EDT - 1 year ago

Tessellate BIO Emerges from Stealth

REPL

Oct 2, 2023, 9:26 PM EDT - 1 year ago

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

Sep 21, 2023, 7:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

Sep 20, 2023, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 19, 2023, 1:10 PM EDT - 2 years ago

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

Aug 14, 2023, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

Aug 7, 2023, 7:15 AM EDT - 2 years ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

Jul 25, 2023, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

Jun 9, 2023, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

masonat Jul. 21 at 3:06 PM

1 · Reply

JarvisFlow Jul. 17 at 11:30 AM

Goldman Sachs has updated their rating for NewAmsterdam Pharma Co ( $NAMS ) to Neutral with a price target of 27.

0 · Reply

Jakeipedia Jul. 12 at 1:03 PM

$VRNA what a massive windfall!!! I’m holding till close Next load for me $MLYS watching $NAMS because of the leadership. Any biotech ideas please share.

3 · Reply

RunnerSignals Jul. 10 at 8:50 PM

comeback kings flex $ACDC $PHAT $PRME $TALO $NAMS bounce off lows, closing the day with a victory dance!

0 · Reply

masonat Jul. 10 at 2:56 PM

0 · Reply

newfguy Jul. 9 at 7:15 PM

$NAMS looks like insiders recognize value and potential

0 · Reply

JFDI Jul. 9 at 2:29 PM

$NAMS perking up

0 · Reply

Biobullshitsniffer Jul. 4 at 8:37 AM

$NAMS That Alzeihmer data in July 27 to 31 is expected to be crap right?

1 · Reply

8869scy Jul. 1 at 6:22 PM

2 · Reply

TrendEdgeLogan Jun. 28 at 5:27 PM

0 · Reply

vinkush1 Jun. 27 at 4:13 AM

$NAMS insider bought should I start a position?

2 · Reply

djohnson591 Jun. 26 at 1:24 PM

$ESPR $NAMS It's coming along nicely 😂😂😂. Here's my prediction: - Dec24 - run NAMS up and do an offering (start to secure massive short) - Dec24 - use NAMS news to start the knockdown of ESPR heading into Q1 - Dec24 - Secure ESPR debt refi - 1stH-25 - Tank ESPR, shift shares around, cover shorts - 1stH-25 - Secure massive short position in NAMS - 2ndH-25 - Announce something that rockets ESPR stock and puts pressure on competitors - 2ndH-25 - Tank NAMS stock and profit on newly secured short position Sound about right? - 😂😂😂 Buying as much ESPR as I can get my hands on bitches!!!

2 · Reply

hschlauch Jun. 22 at 4:19 PM

$ESPR $NAMS $AMGN This referenced study contains major issues. I’ve gone through the actual data and here’s what I found: 1. The separation between “high” and “low” hsCRP groups was split at a median of 1.90 mg/l (50% above and 50% below that point)! Long term HRs for first MACE are typically not significant until well-beyond that point. In fact, the entire study population’s upper quartile begins at an hsCRP of only 3.42 mg/l. That’s like extrapolating data on a group of people smoking a few cigarettes every month and claiming there is sparse evidence for increased cancer risk among ALL cigarette smokers. Increased long term risk of first MACE is barely getting started for hsCRP at 2-3 mg/l.

6 · Reply

BRLondon Jun. 21 at 2:59 PM

$ESPR $NAMS From your own source @masonat BA = statins... But without the main statins side effects...

1 · Reply

Canyonfundstrader2007 Jun. 18 at 10:21 PM

$ESPR $NAMS NEXLIZET #1 Statin Alternative

0 · Reply

Canyonfundstrader2007 Jun. 18 at 10:12 PM

$NAMS $ESPR Studies >

0 · Reply

Canyonfundstrader2007 Jun. 18 at 10:11 PM

$ESPR $NAMS Esperion drug NEXLIZET years ahead & NO side-effects with excellent results 38% to 50% reduction OF LDL & 35% reduced hsCRP levels. Has the only FDA primary prevention label as a statin alternative.

0 · Reply

masonat Jun. 18 at 6:32 PM

$NAMS IL-6 is a far more relevant marker for inflammation in ASCVD than hs-CRP. hs-CRP has no significant predictive value for MACE after adjusting for elevated IL-6. Some drugs that reduce CRP also reduce IL-6 (ie statins, ziltivekimab), but bempedoic acid has no impact on IL-6. Thus, its hs-CRP reduction likely has little to no effect on MACE. One day the ESPR bulls may stop spamming this board with "primary prevention!" and "hs-CRP!" but today is not that day. https://www.atherosclerosis-journal.com/article/S0021-9150(24)00021-2/abstract

1 · Reply

Canyonfundstrader2007 Jun. 18 at 5:33 PM

$ESPR $NAMS $AMGN HUge value

0 · Reply

Canyonfundstrader2007 Jun. 18 at 5:32 PM

$ESPR $NAMS $AMGN extremely valuable

0 · Reply

Canyonfundstrader2007 Jun. 18 at 5:31 PM

$ESPR NEXLIZET & NEXLETOL are the ONLY Statin alternative drugs to lower LDL & HS-CRP levels. They are also the only FDA labeled drugs for primary prevention. $NAMS $AMGN can't compete.

0 · Reply

JarvisFlow Jun. 17 at 12:00 PM

Citigroup has updated their rating for NewAmsterdam Pharma Co ( $NAMS ) to Buy with a price target of 42.

0 · Reply

Market Cap	2.53B
Revenue (ttm)	45.56M
Net Income (ttm)	-241.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-530.29%
Debt to Equity Ratio	0.00

Volume	1,186,100
Avg Vol	859,066
Day's Range	N/A - N/A
Shares Out	112.27M
Stochastic %K	96%
Beta	-0.03
Analysts	Strong Sell
Price Target	$41.18